photonic diagnostics platform
Reader + Biosensor
The future of diagnostics
The Covid-19 pandemic has made it clear that there is a need to have fast and reliable diagnostic tests available in point-of-care (PoC) surroundings. Well-known tests, like the glucose test for diabetes patients, and the pregnancy test are on the market for decades already.
Many other diagnostic tests are still complex, and have to be performed by trained staff on large equipment in specialized facilities. Another setback is that scaling up production of tests, when there is an urgent need for large numbers, is cumbersome and time-consuming, like has been seen during the afore mentioned pandemic.
In the last decade, new biosensor technologies have emerged that allow the sensitive and quantitative detection of biomarkers (indicator molecules, e.g. specific proteins or DNA) for conditions like cancer, cardiovascular and infectious diseases.
Surfix works on one of those new biosensor technologies, the photonic biosensor. This ultra-sensitive, fast, and label-free technology harbours the possibility of detecting multiple biomarkers at the same time. Features that, along with a low unit cost and the ability to easily scale up production, will revolutionize the world of medical diagnostics by enabling PoC diagnosis and treatment monitoring of a wide variety of conditions.
Photonic biochips use light instead of electricity to detect the presence of biomarkers. The light travels through a spiral-shaped structure on the chip, comparable to a miniature optical fiber.
Receptor molecules that are coated onto the surface of the photonic biochip can selectively catch and bind specific biomarkers in a sample, based on biorecognition.
The interaction between the receptor molecules and the biomarkers causes a change in the properties of the light that is travelling through the chip. This change is detected and translated into a useful diagnostic result, e.g. information about the presence or the concentration of a certain biomarker in the sample.
The Surfix biosensor combines the photonic biochip with a microfluidic cartridge, in which the sample is processed and the biological assay takes place in a small sample volume. This is comparable to a miniaturized and automated laboratory procedure.
When the sample is ready for analysis, it is transported to the photonic biochip. The signal read-out of the photonic biosensor is performed with a desktop reader.
Both the photonic biochip and the microfluidic cartridge benefit from unique nanocoatings, which enhance the sensitivity of the sensor and the flow of the sample, and reduce unwanted binding of biomolecules.
The plug-and-play platform is the heart of Surfix’s concept in which you, our client and partner, provide the diagnostic application, i.e. the receptor molecule and/or the biomarker you wish to detect. The platform can be used to detect any biomarker, like proteins (antibodies or antigens), nucleic acids (DNA or RNA), viruses, etc.
Surfix combines the photonic biochip and the microfluidic cartridge with smart technologies for fluidic and optical interfacing in a streamlined process flow.
Surfix offers dedicated solutions for assay development, and for scalable production of PoC devices in medical, agri-food, environmental monitoring, or any other application area!
Artist impression of Surfix’s photonic chip, showing the spiral-shaped structure (white) embedded in the chip like a miniature optical fiber (real dimensions: approx. 0.5 x 0.3 mm2).
Artist impression of Surfix’s photonic biochip with receptor molecules (green, Y-shaped) on the spiral-shaped structure and biomarker molecules (orange spheres).
Our goal is to get you a low-cost, fast, and ultrasensitive diagnostic test
Are you currently using a complicated, time-consuming or expensive test? Contact us!